Pfizer: positive data in Covid-19 for adolescents
(CercleFinance.com) - Pfizer and BioNTech have announced initial positive results from a longer-term analysis evaluating the safety and efficacy of their Covid-19 vaccine in adolescents aged 12 to 15 years.
They say the updated results from the pivotal Phase 3 trial show that a two-dose series (30 μg per dose) is 100% effective against the disease, measured seven days to over four months after the second dose, with no serious safety issues identified.
This data will form the basis of an application to be submitted to the FDA to expand approval of the vaccine for use in people aged 12 years and older. The product is already available for 12-15 year olds under the emergency use authorization.
Copyright (c) 2021 CercleFinance.com. All rights reserved.